

Completion of recruitment to a prospective, open-label clinical investigation of Arthrosamid for knee osteoarthritis

October 17, 2019: Contura is pleased to announce that in September 2019 it completed recruitment for a prospective, open-label clinical investigation of Arthrosamid in subjects with knee osteoarthritis. The study involved the recruitment of nearly fifty patients at three specialist treatment centers in Denmark. The study will measure the reduction in pain achieved at 3 months, 6 months and 12 months following a single injection of Arthrosamid. The study, which will be conducted in accordance with ISO 14155, is the second major clinical study commenced by the company for Arthrosamid in 2019.

Commenting on study, Patrick Banks, Chief Executive of Contura said: ***"Following the Company's commencement of its multi-center, randomized, controlled clinical study of Arthrosamid in knee osteoarthritis in May 2019, we decided to perform this follow-on study with a view to expediting the regulatory approval of Arthrosamid in Europe. This study will be performed in accordance with the requirements of ISO 14155 and its results will form the basis of a regulatory filing for product approval in Europe. Three month results from the study should be available in the first quarter of 2020."***

About Arthrosamid

Arthrosamid is a polyacrylamide hydrogel developed by Contura as a long-lasting intra-articular injection for the treatment of osteoarthritis in humans. Development of Arthrosamid commenced after the generation of impressive clinical data with Arthramid Vet, a related product of the company, in the treatment of lameness in horses. Arthrosamid has the effect of thickening the synovial membrane, thereby providing increased cushioning and other therapeutic benefits to patients with osteoarthritis. Patients benefit from both pain relief and improved mobility.

About Osteoarthritis of the Knee

Osteoarthritis is the most common form of arthritis, characterized by pain and physical disability. More than 10% of people over the age of 55 suffer from symptomatic osteoarthritis, primarily involving the knees. Due to the pivotal role of the knee in basic mobility, knee osteoarthritis is associated with significant impairments and limitations in basic activities of daily living, such as walking and moving around, self-care and participation in activities, all contributing to a reduced quality of life. There is a drought of available effective treatments for knee osteoarthritis today. Even the widely used hyaluronic acids are accepted to have limited efficacy and work for limited duration.

14 Took's Court, London EC4A 1LB

T: +44 (0) 20 7421 7400 **F:** +44 (0) 20 7421 7401

Company Number: 03145216 (Registered in England and Wales)

About Contura

Contura is headquartered in London and has its manufacturing facility in Copenhagen, Denmark. It specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily in women's health. Its lead products are Bulkamid®, Aquamid®, Regurin® XL and Cystistat®. It also has a number of ongoing development programmes focused upon additional uses of its proprietary hydrogel technology, one of which is Arthrosamid® for the treatment of osteoarthritis in the knee. Contura has an established sales and marketing infrastructure in the leading European and worldwide markets, either through its own sales force or through distribution partners. It has its own offices in the UK, Denmark, Germany, France and Italy, currently employing around 45 staff worldwide.

-ENDS-

Contact:

For further information please contact the Contura Press Office (managed by Trinity PR) on +44 20 7112 4905 / +44 770 948 7959 / jo.hudson@trinitypr.co.uk

www.contura.com